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Extracellular MRP8/14 is a regulator of b2
integrin-dependent neutrophil slow rolling
and adhesion
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Myeloid-related proteins (MRPs) 8 and 14 are cytosolic proteins secreted from myeloid cells
as proinflammatory mediators. Currently, the functional role of circulating extracellular
MRP8/14 is unclear. Our present study identifies extracellular MRP8/14 as an autocrine
player in the leukocyte adhesion cascade. We show that E-selectin–PSGL-1 interaction during
neutrophil rolling triggers Mrp8/14 secretion. Released MRP8/14 in turn activates a TLR4-
mediated, Rap1-GTPase-dependent pathway of rapid b2 integrin activation in neutrophils.
This extracellular activation loop reduces leukocyte rolling velocity and stimulates adhesion.
Thus, we identify Mrp8/14 and TLR4 as important modulators of the leukocyte recruitment
cascade during inflammation in vivo.
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M
yeloid-related protein 8 (MRP8, also known as S100A8
or calgranulin A) and myeloid-related protein 14
(MRP14, S100A9, calgranulin B) are two members of
the S100 family, characterized by two calcium-binding EF-hand
motifs, which are connected by a central hinge region1,2. They form
a heterocomplex (MRP8/14, also known as calprotectin), which is
considered to be the physiologically relevant form3, and are found
in the cytosol of neutrophils representing 40% of the cytosolic
protein content in neutrophils4. The Mrp8/14 complex is released
from myeloid cells during inflammatory events through an
alternative, Golgi-independent route1,2 and exerts its
proinflammatory effect on endothelial cells5, phagocytes6–8 and
lymphocytes9. Recently, it has been shown that Mrp8/14 may also
be involved in the regulation of adaptive immune responses10.
Several inflammatory disorders including chronic bronchitis11,
inflammatory bowel disease12,13, rheumatoid arthritis14, psoriasis15
or systemic-onset juvenile idiopathic arthritis16 are associated with
elevated serum levels of MRP8/14. As a consequence, these proteins
are suitable biomarkers of inflammation and are used to monitor
the response towards anti-inflammatory therapy14,17,18.
Interestingly, the exact function of serum-circulating MRP8/14
during an inflammatory response has remained elusive. This has
also been attributed to the fact that the intracellular function of
MRP8/14 may be fundamentally different to its extracellular
function as an alarmin molecule1.
In inflammation, leukocyte recruitment follows a defined
cascade of adhesion and activation events beginning with
selectin-mediated leukocyte capture to and rolling along the
inflamed endothelium19,20. This triggers intermediate activation
of b2 integrins and consecutive slowing down of the
rolling leukocytes. Furthermore, rolling facilitates binding of
leukocyte-expressed chemokine receptors to their cognate
chemokines presented on the luminal endothelial surface.
This in turn induces, together with E-selectin, binding to
P-selectin glycoprotein-1 (PSGL1) and full activation of b2
integrins21,22 leading to firm leukocyte adhesion to the
endothelial surface.
Extracellular MRP8/14 is thought to influence different steps
along the leukocyte recruitment process via binding to surface
receptors including the Toll-like receptor-4 (TLR4) and the
receptor of advanced glycation endproducts (RAGE). It has been
shown that extracellular MRP8/14 induces endothelial secretion
of the inflammatory chemokine CXCL8 (CXC chemokine ligand
8 also known as IL8) and upregulates Intercellular Adhesion
Molecule 1 (ICAM-1) on human microvascular endothelial cells
(HMECs) in vitro5. In addition, cellular permeability of MRP8/
14-stimulated-HMEC monolayers increased5. Concerning the
effect of MRP8 and MRP14 on leukocyte adhesion, Newton and
Hogg showed that human MRP14 stimulates neutrophil adhesion
to fibrinogen by activating the b2 integrin Mac-1 (ref. 7). Despite
recent progress regarding the function of extracellular MRP8 and
MRP14 on leukocyte recruitment, the molecular mechanisms
triggering the release of MRP8/14 into the extracellular
compartment and the functional outcomes of such a release
have remained elusive. In our study, which focused on the
extracellular function of MRP8/14, we show that neutrophil
rolling on E-selectin present on inflamed endothelium leads to
Mrp8/14 secretion. Extracellular Mrp8/14 in turn acts in an
autocrine manner through an extracellular activation loop via
binding to its receptor TLR4 on neutrophils, which subsequently
induces the activation of Rap1 and b2 integrins and neutrophil
slow rolling and firm arrest. Thus, we present a novel mechanism
of rapid TLR4-induced b2 integrin activation involving
extracellular MRP8/14 as a modulator of leukocyte recruitment
that bridges the steps of rolling and adhesion during an
inflammatory response in vivo.
Results
E-selectin triggers Mrp8/14 release in vitro and in vivo. Recent
studies showed that MRP8/14 was released during the interaction
of activated monocytes with tumor-necrosis factor (TNF)-a-sti-
mulated, but not resting human umbilical vein endothelial cells
(HUVECs)16. Here, we investigated which signals on the
inflamed endothelium were able to induce MRP8/14 release
from activated phagocytes. To this end, we isolated bone marrow-
derived neutrophils from C57BL/6 wild-type (WT) mice and
incubated the cells at 37 C in wells pre-coated with E-selectin-Fc,
P-selectin-Fc or PBS. Soluble phorbol myristate acetate (PMA)
was used as a positive control. Supernatants were collected 10 and
30min thereafter and analysed for Mrp8/14 by ELISA as
described previously23. Incubation (10min) of isolated
neutrophils with PBS induced Mrp8/14 secretion
(42±4 ngml 1; Fig. 1a). Secretion was significantly increased
in the presence of E-selectin (96±13 ngml 1) and PMA
(118±12 ngml 1). In contrast, the presence of P-selectin failed
to induce a significant increase in Mrp8/14 release
(64±11 ngml 1) in this assay. Addition of rat anti-mouse
E-selectin antibody 9A9 inhibited E-selectin-induced Mrp8/14
release (39±5 ngml 1; Fig. 1b). Fc control was unable to induce
Mrp8/14 release (30±7 ngml 1). Similar results were found
after 30min incubation (PBS: 52±8 ngml 1, E-selectin:
108±17 ngml 1 and P-selectin: 56±7 ngml 1) with the
exception of PMA, which further increased the release of
Mrp8/14 (230±25 ngml 1; Fig. 1c).
To evaluate E-selectin involvement in Mrp8/14 secretion under
in vivo conditions, we injected recombinant mouse TNF-a
(rmTNF-a) into the scrotum of C57BL/6 WT mice with or
without intravenous (i.v.) injection of E-selectin-blocking mono-
clonal antibody 9A9 (30 mg per mouse) 15min before rmTNF-a
application. Mrp8/14 serum levels were measured before and 2 h
after rmTNF-a treatment by ELISA. Mrp8/14 serum levels
of untreated mice were 249±66 and 273±105 ngml 1,
respectively. Application of rmTNF-a increased serum levels of
Mrp8/14 to 5,590±1,013 ngml 1. Pretreatment of mice with
anti E-selectin blocking monoclonal antibody 9A9 significantly
reduced serum levels of Mrp8/14 to 2,292±206 ngml 1,
indicating that E-selectin is involved in Mrp8/14 release in vivo
(Fig. 1d). In a second set of experiments, we depleted neutrophils
from mouse blood to prove that serum Mrp8/14 is neutrophil-
derived in this in vivo model. For this approach, we pretreated
mice with anti-Ly6C antibody 1A8 (30 mg per mouse) 24 h before
rmTNF-a treatment. Mrp8/14 serum levels of neutrophil-
depleted mice were 130±19 ngml 1 before rmTNF-a treatment
and 2,100±505 ngml 1 after rmTNF-a treatment (Fig. 1d).
These findings highlight that neutrophils are a central source of
serum circulating Mrp8/14 under inflammatory conditions.
E-selectin-triggered Mrp8/14 release is PSGL1 dependent.
Under in vivo conditions, E-selectin is known to bind to three
different ligands on mouse neutrophils: PSGL1 (gene name:
Selpl), CD44 and ESL1 (gene name: Glg1)24. To identify the
E-selectin ligand responsible for E-selectin-triggered Mrp8/14
release, we isolated bone marrow neutrophils from C57Bl/6 WT,
Selpl / and Cd44 / mice, as well as from mice with a
Glg1-deficient haematopoietic system. We incubated the cells on
wells coated with PBS or E-selectin for 10min, collected the
supernatants and analysed the samples for Mrp8/14 release by
ELISA as described23 (Fig. 2a). PMA was used as a positive
control (Fig. 2b). Lack of CD44 did not influence the capability of
cells to secrete Mrp8/14. Cd44 / cells incubated with PBS
secreted 35±3 ngml 1 Mrp8/14. Incubation of the cells with
E-selectin increased the levels to 75±9 ngml 1 (Fig. 2a). Cells
from Glg1 / - and Selpl / -deficient mice exhibited an
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increased basal Mrp8/14 release as compared with C57BL/6 WT
or Cd44 / cells (93±40 ngml 1 and 97±25, respectively).
Glg1 / -deficient cells stimulated with E-selectin showed a
slight, however, not significant, increase in Mrp8/14 secretion
(137±37 ngml 1). Selpl / cells incubated on E-selectin-
coated plates were unable to increase Mrp8/14 levels as
compared with levels induced by PBS (110±27 ngml 1).
These results suggest an involvement of PSGL-1 in E-selectin-
triggered Mrp8/14 release. Whether ESL1 may have an additional
role in E-selectin-dependent secretion of Mrp8/14 is not
entirely clear and needs further investigation. Secretion of
Mrp8/14 upon PMA stimulation was not affected in
Cd44 / -, Glg1 / - and Selpl / -deficient cells (120±18,
288±65 and 184±31 ngml 1, respectively, Fig. 2b).
Released Mrp8/14 binds to TLR4 in an autocrine manner.
Next, we tested the ability of released (soluble) Mrp8/14 to bind
to leukocytes in an autocrine manner. For this approach, bone
marrow cells from C57BL/6 WT mice were isolated and stimu-
lated for 5min at 37 C with or without (control) soluble
E-selectin. Mrp8/14 on neutrophils was detected using a poly-
clonal anti-mouse Mrp14 antibody, followed by a fluorescently
labelled secondary antibody. As TLR4 is considered the main
cellular surface receptor of Mrp8/14 on leukocytes23, experiments
were performed in the absence or presence of rat anti-mouse
TLR4 antibody 1A6 or IgG2b control. The amount of
extracellular surface-bound Mrp14 protein on Ly6Gþ /Mrp14þ
leukocytes was determined using FACS analysis. As shown in
Fig. 2c, cells stimulated with E-selectin showed a 20% higher
amount of Mrp14 protein (factor 1.20±0.04%) on the cellular
surface compared with control cells. Addition of anti-mouse
TLR4 antibody 1A6 completely abolished the ability of released
Mrp14 protein to bind to neutrophils (factor 1.01±0.06),
suggesting that released Mrp8/14 can bind to TLR4 in an
autocrine manner. For representative FACS plots, see
Supplementary Fig. 1.
MRP8/14 activates b2 integrins via TLR4. Next, we investigated
the effects of the MRP8/14–TLR4 interaction on the
activation status of b2 integrins. Owing to the lack of antibodies
recognizing the activation status of b2 integrins in mice,
we performed the following experiments using human blood
neutrophils where respective activation-specific antibodies are
available. We enriched neutrophils from healthy blood donors
and stimulated the cells for 5min at 37 C with or without
granulocytic human MRP8/14 (hMRP8/14) or lipopolysaccharide
(LPS), another known TLR4 ligand. The activation status
of b2 integrins was analysed by FACS using the b2 integrin
activation markers KIM127 and mAB24 (ref. 25). Interestingly,
both hMRP8/14 and LPS were able to convert b2 integrins
into an activated form. Neutrophils incubated with hMRP8/14
showed 1.38±0.08-fold higher KIM127 antibody binding
compared with control neutrophils (Fig. 3a). Incubation with
LPS increased binding of KIM127 by a factor of 1.44±0.03. To
prove that measured b2 integrin activation was indeed induced
via hMRP8/14 interaction with TLR4, we pretreated human
neutrophils with polyclonal rat anti-human TLR4 antibody or
Paquinimod (ABR215757), respectively, before incubating
the cells with hMRP8/14. Paquinimod is a small-molecule
inhibitor, which blocks binding of MRP8/14 to its receptor
TLR4 (refs 26,27). Both Paquinimod and polyclonal rat
anti-human TLR4 antibody abolished the activation of b2
integrins by hMRP8/14. Binding of mAB24 antibody was
increased by a factor of 1.56±0.06 and 1.96±0.1 when
cells were incubated with hMRP8/14 or LPS, respectively, as
compared with control (Fig. 3b). Again, we were unable to
measure b2 integrin activation by hMRP8/14 in the presence of
Paquinimod or anti-human TLR4 antibody using activation-
specific mAB24 antibody (factor 1.05±0.05 and 1.00±0.03,
respectively). For representative histogramm plots, see
Supplementary Fig. 2a,b. Surface expression levels of total LFA-1


























































































Figure 1 | Interaction of neutrophils with E-selectin results in Mrp8/14 release in vitro and in vivo. Bone marrow-derived neutrophils from C57BL/6 WT
mice were incubated at 37 C in wells pre-coated with E-selectin, P-selectin or PBS. Soluble PMA was used as positive control. Supernatants were collected
and analysed by ELISA. Mrp8/14 secretion (mean±s.e.m., nZ5 mice per group, one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test)
induced by E-selectin (grey bar), PMA (black bar) and P-selectin (light grey bar) is shown after 10min (a) and 30min (c) incubation. (b) Mrp8/14
secretion (mean±s.e.m., nZ3 mice per group, one-way ANOVA with Dunnett’s post-hoc test) after 10min induced by human Fc control (white spotted
bar), E-selectin (grey bar, same bar as in a) and E-selectinþ anti E-selectin antibody 9A9 (grey spotted bar). PBS was used as control (white bar, same bar
as in a). (d) In vivo Mrp8/14 secretion induced by E-selectin: rmTNF-a was injected into the scrotum of C57BL/6 WTmice without or with E-selectin
blockade (9A9) and after neutrophil depletion (nZ3 mice per group, two-way ANOVA with Tukey’s post-hoc test).
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MRP8/14 activates Rap1 via TLR4. The small GTPase Rap1 is
involved as an intermediate of the E-selectin-triggered activation
of b2 integrins and of the inside out signalling activation of
integrins via G-protein-coupled receptors during leukocyte
recruitment28. In its role as upstream molecule of inside-out
signalling-mediated b2 integrin activation, it regulates binding
affinity of b2 integrins and therefore rolling velocities and
adhesive properties28. Here we wanted to test whether active
Rap1 (GTP-Rap1) is also induced by hMRP8/14. For this
approach, human neutrophils isolated from healthy blood
donors were stimulated for 5min at 37 C in the presence or
absence of hMRP8/14. Recombinant human E-selectin was used
as positive control. Both hMRP8/14 and E-selectin induced an
upregulation of Rap1-GTP in neutrophils (Fig. 4, left panels).
Pretreatment of the cells with Paquinimod (Fig. 4a,b) or rat anti-
human TLR4 antibody (Fig. 4c,d) abolished hMRP8/14- and
E-selectin-induced Rap1 activation demonstrating that E-selectin,
as well as hMRP8/14-triggered activation of Rap1 is dependent on
TLR4. Full immunoblots are shown in Supplementary Fig. 4a,b.
Heat inactivation of hMRP8/14 and E-selectin prevented Rap1
activation, excluding any relevant LPS contamination of proteins
used in this assay (Supplementary Fig. 4b).
Mrp8/14 reduces rolling velocity of neutrophils. As the acti-
vation status of b2 integrins directly influences leukocyte rolling
velocity, we investigated the influence of secreted Mrp8/14 on
leukocyte rolling behaviour. For this purpose, we used a slightly
modified microflow chamber system29 coated with recombinant
mouse E-selectin (rmE-selectin) alone or in combination with
recombinant mouse ICAM-1 (rmICAM-1). The combination of
rmE-selectin and rmICAM-1 mediates slow rolling of neutrophils
and reflects the in vivo situation of cells rolling on TNF-a-
stimulated postcapillary venules21. Whole mouse blood was
obtained via a carotid artery catheter, heparinized and perfused
through the microflow chamber using a high precision perfusion
pump at a shear stress level of 2.7 dyn cm 2 (nZ3 mice per
group). Leukocytes from untreated control blood rolled at a
velocity of 0.50±0.02 mms 1 on rmE-selectin-coated glass
capillaries (Fig. 5a). A combination of rmE-selectin/rmICAM-1
reduced rolling velocity significantly to 0.36±0.02 mms 1. This
ICAM-1-dependent reduction is in accordance to previous
findings21,30 and reflects the previously described E-selectin-
induced intermediate activation of b2 integrins on leukocytes21.
To test whether E-selectin-regulated rolling velocity depends on













































































































































Figure 2 | E-selectin-triggered Mrp8/14 release is PSGL1-dependent and -independent of CD44. Bone marrow neutrophils were isolated from C57Bl/6
WT, Selpl / , Cd44 / and Glg1 / mice and incubated on wells coated with PBS or E-selectin (a) or incubated with PMA (b) for 10min. Supernatants
were collected and Mrp8/14 release was determined by ELISA (nZ3 mice per group, paired t-Test). Data are presented as mean±s.e.m. In addition,
Mrp8/14 binding to TLR4 on leukocytes was assessed (c). Bone marrow cells from C57BL/6 WTmice were isolated and stimulated for 5min at 37 C with
or without soluble rmE-Selectin. The amount of extracellular surface-bound Mrp14 protein on Ly6Gþ /Mrp14þ leukocytes was determined by flow
cytometry. Mean fluorescence intensity values of cells stimulated without E-Selectin (control) were set to 1 (white bar) and values of E-selectin-stimulated
cells were calculated as mean ratio compared with control. Data are presented as mean±s.e.m. (n¼4 mice per group, unpaired t-test).
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investigated leukocyte rolling velocity on rmE-selectin/rmICAM-
1-coated capillaries in the presence or absence of Paquinimod as
well as in the presence or absence of rat anti-mouse TLR4
antibody 1A6. Addition of Paquinimod to the blood resulted in
an increase in leukocyte rolling velocity to 0.51±0.04 mms 1
(Fig. 5b). In line with this finding, the presence of anti-mouse
TLR4 antibody 1A6 resulted in an increase in rolling velocity to
0.51±0.02 mms 1. Rat IgG2b isotype control did not change the
rolling velocities of cells rolling on rmE-selectin/rmICAM-1 when
compared with untreated control cells (0.31±0.01 mms 1). In
addition, application of Lovastatin, which has been demonstrated
to keep b2-integrins in their low-affinity status31, resulted in a
mean rolling velocity of 0.57±0.05 mms 1. Unexpectedly, whole
blood cells from Tlr4-deficient mice (Tlr4 / ) did not show an
increased rolling velocity (Fig. 5c). Cells from Tlr4 / mice
rolled with a mean rolling velocity of 0.31±0.01 mms 1.
However, presence of Paquinimod did not influence rolling
velocity of Tlr4 / cells (0.33±0.02 mms 1), indicating that

























































































Figure 3 | MRP8/14 activates b2 integrins via TLR4. Neutrophils from
healthy blood donors were stimulated for 5min at 37 C with or without
human MRP8/14 (hMRP8/14) or LPS. In some experiments, cells were
preincubated with rat anti-human polyclonal TLR4 antibody or Paquinimod.
Activation status of b2 integrins was determined using flow cytometry.
Gates were set by using an isotype control. Values of KIM127 and mAB24
binding from unstimulated control was set to 1. (a) KIM127 binding and
(b) mAb24 binding: control neutrophils (n¼ 9, white bar), neutrophils
incubated with hMRP8/14 (n¼ 9, black bar), neutrophils incubated with
LPS (n¼ 3, white lined bar). Preincubation of hMRP8/14-stimulated cells
with Paquinimod or polyclonal rat anti-human TLR4 antibody reduced
KIM127 binding to control levels (n¼6, grey spotted bar and n¼ 3, grey
bar, respectively). Data are presented as mean±s.e.m., one-way analysis of







































































































Figure 4 | MRP8/14 activates Rap1. Representative immunoblots are
shown for total Rap1 and Rap1-GTP from human neutrophils stimulated with
PBS/0.1% BSA (control), human MRP8/14 (hMRP8/14) or recombinant
human E-selectin (E-selectin) without (left panel, w/o) or with Paquinimod
(right panel, Paquinimod; a) and without (left panel, w/o) or with rat anti-
human TLR4 antibody 1A6 (right panel, 1A6; c). Density blots were
calculated using Image J software (b,d). Data are presented as
mean±s.e.m. (n¼ 3 per group, one-way analysis of variance with
Dunnett’s post-hoc test).
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but due to another, yet undefined mechanism. To also test a
potential contribution of another Mrp8/14 receptor, RAGE,
for Mrp8/14-induced slow leukocyte rolling velocity, we used
whole blood from Rage-deficient mice (Rage / ). In contrast to
Tlr4 / cells, we found leukocyte rolling velocities in Rage-
deficient mice (0.52±0.03 mms 1 with Paquinimod versus
0.36±0.02 mms 1 without Paquinimod, Fig. 5c), which were
comparable to WT cells. These findings indicate that RAGE is not
involved as relevant receptor for Mrp8/14-dependent regulation
of rolling velocity. Next, we investigated potential downstream
signalling molecules involved in TLR4-dependent b2 integrin
activation and slow rolling. For this approach, we pretreated
C57BL/6 WT mice by intraperitoneal (i.p.) injection of either
control peptide or MyD88 inhibitor IMG2005. Twenty-four
hours later, a carotid artery catheter was placed and rolling
velocity of leukocytes investigated via an ex vivo flow chamber
system29. Leukocytes from C57BL/6 WT mice treated with









































































































































Figure 5 | Mrp8/14 reduces rolling velocity of neutrophils in vitro and in vivo. Whole mouse blood was perfused through microflow chambers (shear
stress 2.7 dyn cm 2, nZ3 mice per group). (a) Leukocytes rolling velocities of C57BL/6 WTmice were assessed in rmE-selectin (n¼ 209 cells) and rmE-
selectin/rmICAM-1-coated glass capillaries (n¼ 178 cells). For rmE-selectin/rmICAM-1-coated glass capillaries, leukocyte rolling velocities were assessed
for (b) untreated leukocytes (white bar, same bar as in a), Paquinimod-treated leukocytes (n¼ 97 cells, grey spotted bar), rat IgG2b isotype-treated
leukocytes (n¼ 165 cells, black bar), anti-TLR4 antibody 1A6-treated leukocytes (n¼ 184 cells, light grey bar) and Lovastatin-treated leukcoytes (n¼ 65
cells, grey lined bar). In addition, leukocyte rolling velocities from C57BL/6 WTmice were assessed for (c) untreated leukocytes (white bar, same bar as in
a and b), from Tlr4 / mice for untreated leukocytes (n¼ 271 cells, grey bar) or Paquinimod treated leukocytes (n¼ 182 cells, grey spotted bar) and from
Rage / mice for untreated leukocytes (n¼ 88 cells, dark grey bar) or Paquinimod-treated leukocytes (n¼ 140 cells, dark grey spotted bar). (d) Ex vivo
leukocyte rolling velocities of cells treated with control peptide (n¼ 140 cells, white bar) or MyD88 inhibitor IMG2005 (n¼ 160 cells, grey bar) were
assessed. (e) In vivo leukocyte rolling velocities were analysed in rmTNF-a-stimulated venules of mouse cremaster muscles of C57BL/6 WTmice,
pretreated with PBS/10% DMSO as control (n¼ 98 cells, white bar) or pretreated with Paquinimod (n¼ 71 cells, grey spotted bar). (f) In addition,
in vivo rolling velocity was assessed for mice pretreated with rat IgG2b isotype control (n¼ 225 cells, white bar) or pretreated with rat anti-mouse
TLR4 antibody 1A6 (n¼ 214 cells, light grey bar). Data are presented as mean±s.e.m. (a,d,e,f) unpaired t-test, (b,c) one-way analysis of variance
with Dunnett’s post-hoc test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7915
6 NATURE COMMUNICATIONS | 6:6915 | DOI: 10.1038/ncomms7915 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
0.32±0.01 mms 1 (Fig. 5d). Application of IMG2005 increased
rolling velocity to 0.53±0.02 mms 1. Taken together, our results
suggest that slow b2 integrin-mediated leukocyte rolling velocity
on rmE-selectin/rmICAM-1-coated capillaries is critically
dependent on Mrp8/14, TLR4 and MyD88 in C57Bl/6 WT mice.
To address the in vivo relevance of our in vitro findings in the
flow chamber, we used C57BL/6 WT mice and analysed leukocyte
rolling velocities in rmTNF-a-stimulated mouse cremaster
muscle venules in the presence or absence of Paquinimod.
Leukocyte slow rolling depends on E-selectin and the b2 integrins
LFA-1 and Mac-1 in this model, as described previously32. Mice
were pretreated with Paquinimod (10 mg g 1 mouse) or carrier
substance (control, PBS/10% dimethylsulphoxide (DMSO)) i.p.
1 h before rmTNF-a application. Application of Paquinimod
did not affect the number of circulating leukocytes (3,787±
420 cells ml 1 for PBS/10% DMSO and 3,754±87 cells ml 1 for
Paquinimod-treated mice, respectively). Leukocytes of control
mice rolled with a mean velocity of 3.79±0.34 mms 1 (Fig. 5e).
Pretreatment of mice with Paquinimod resulted in a significant
increase in rolling velocity compared with control mice with a
rolling velocity of 7.50±0.65 mms 1. In a different set of
experiments, we pretreated mice via i.p. injection of 30mg rat
anti-mouse TLR4 antibody 1A6 or rat IgG2b isotype control 1 h
before rmTNF-a application. Cells from mice treated with rat
IgG2b isotype control displayed a mean velocity of
3.41±0.12 mms 1 (Fig. 5f). Pretreatment of mice with rat anti-
mouse TLR4 antibody 1A6 resulted in an increase in rolling
velocities (7.20±0.39 mms 1), which were similar to levels seen
in Paquinimod-treated mice, suggesting that Mrp8/14 and its
receptor TLR4 regulate leukocyte rolling velocity in vivo.
Mrp8/14 increases leukocyte adhesion in vivo. Finally, we tested
the impact of Mrp8/14 on leukocyte adhesion in vivo. It was
shown previously that in the TNF-a-stimulated inflammation
model of the mouse cremaster muscle, blockade of chemokine-
induced inside-out signalling by pertussis toxin (PTx) resulted in
a markedly reduced number of adherent cells in postcapillary
venules of E-selectin  / (Sele / ) mice33. In contrast,
exclusive blocking of Gai-coupled chemokine receptors by PTx
or exclusive lack of E-selectin did not significantly alter leukocyte
adhesion in TNF-a-stimulated cremaster muscle venules33. To
demonstrate that Mrp8/14 and TLR4 are involved in E-selectin-
triggered leukocyte adhesion, C57BL/6 WT mice were pretreated
with PaquinimodþPTx or PBS/10% DMSO (carrier substance,
control)þPTx i.p. 1 h before rmTNF-a application. In a second
set of experiments, C57BL/6 WT mice were pretreated with rat
anti-mouse TLR4 antibody 1A6þPTx or IgG2b þPTx.
RmTNF-a was applied to the mouse scrotum and 2 h later
mouse cremaster muscle was dissected. Intravascular number of
adherent cells per mm2 was analysed as described before34.
The number of adherent cells per mm2 was significantly
reduced in the presence of Paquinimod and PTx (427
±36 cells mm 2, Fig. 6a), as compared with control
conditions (1,016±84 cells mm 2). Consistently, rat IgG2b
isotype controlþPTx did not influence the number of adherent
cells per mm2 (1,088±57 cells mm 2), whereas the presence
of 1A6þPTx reduced the number of adherent cells to 500
±32 cells mm 2. Representative pictures are shown in Fig. 6b,
representative video clips are presented in Supplementary Movies
1 and 2. Application of Paquinimod or 1A6 alone (without PTx)
did not significantly reduce the number of adherent cells per mm2
as compared with control conditions (DMSO/10% PBS or IgG2b
alone; Supplementary Fig. 5).
To exclude potential additive effects of E-selectin-induced
adhesion and Mrp8/14-TLR4-induced adhesion, we additionally
pretreated mice with a combination of anti-E-selectin antibody
9A9þPaquinimodþ PTx or a combination of 9A9þ 1A6þPTx.
Finally, we pretreated mice with a combination of
Paquinimodþ 1A6þ PTx (Fig. 6c). None of these combinations
further reduced the number of adherent cells per mm2 in TNF-a-
stimulated mouse cremaster model (472±58, 429±47 and
528±41 cells mm 2, respectively). These findings suggest that
E-selectin-triggered release of Mrp8/14 interacts with TLR4 to
regulate leukocyte adhesion in vivo.
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Figure 6 | Mrp8/14 increases leukocyte adhesion in TNF-a-stimulated
cremaster muscle venules in vivo. (a) C57BL/6 WTmice were pretreated
with carrier substance (PBS/10% DMSO, control)þ PTx (white bar),
a combination of Paquinimodþ PTx (grey spotted bar), rat IgG2b isotype
controlþ PTx (black bar) or a combination of rat anti-mouse TLR4 antibody
1A6þ PTx (light grey bar). (b) One representative micrograph is shown.
(c) C57BL/6 WTmice were pretreated with a combination of
Paquinimodþ PTx (grey spotted bar, same bar as in a), a combination of
1A6þ PTx (light grey bar, same bar as in a), a combination of rat anti-
mouse E-selectin Ab 9A9þ Paquinimodþ PTx (grey spotted bar), a
combination of 9A9þ 1A6þ PTx (light grey lined bar) or a combination of
1A6þ Paquinimodþ PTx (light grey spotted bar). Data are presented as
mean±s.e.m. of at least three mice per group, one-way analysis of variance
with Tukey’s post-hoc test.
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Discussion
Leukocyte recruitment during inflammation follows a well-
defined cascade of adhesion and activation events starting with
tethering and rolling of leukocytes along the inflamed endothe-
lium19. During rolling, integrins expressed on leukocytes undergo
conformational changes from a low-affinity bent conformation to
an intermediate and finally high-affinity open conformation
leading to leukocyte slow rolling and adhesion35. Here, we
present a new MRP8/14-dependent extracellular activation loop
for b2 integrin activation and hence leukocyte recruitment in vivo
(illustrated in Fig. 7). We show that during E-selectin-dependent
leukocyte rolling, the ligation of PSGL1 by E-selectin induces the
release of Mrp8/14 complex from neutrophils. Released Mrp8/14
in turn binds to TLR4 expressed on neutrophils, which triggers
the activation of Rap1 (Rap1-GTP) leading to intermediate and
full-activation of b2 integrins. Using the inhibitor Paquinimod,
which blocks binding of Mrp8/14 to its receptor TLR4
(refs 26,27), we demonstrate that rapidly released Mrp8/14 and
neutrophil-expressed TLR4 are a new axis for the regulation of
integrin activation thereby affecting integrin-dependent steps of
leukocyte recruitment, that is, slow leukocyte rolling and firm
leukocyte arrest.
It has been known for several years that activated phagocytes
secrete MRP8/14 during inflammatory responses via an alter-
native pathway bypassing the classical Golgi-route2. The secretion
was described to be induced during the contact of monocytes with
TNF-a-stimulated HUVEC, but not with resting HUVEC16.
Serum levels of MRP8/14, also known as calprotectin, are strongly
elevated during several inflammatory processes11–16 and the
protein complex is used as an inflammatory biomarker for many
years. However, the exact molecules involved in MRP8/14 release
and the functional role of serum-circulating MRP8/14 during
inflammation remained undefined. Previous studies have
suggested that engagement of E-selectin with PSGL-1 during
leukocyte rolling on inflamed endothelium triggers an
intracellular signalling cascade leading to Rap1-GTP-dependent
activation of b2 integrins21,22,30, which results in leukocyte slow
rolling (reviewed in ref. 22). Our study indicates that engagement
of E-selectin with PSGL-1 does not directly activate Rap1-GTP
and b2 integrins, but requires an additional extracellular
activation loop involving E-selectin-dependent release of
Mrp8/14 with consecutive binding of extracellular Mrp8/14 to
neutrophil-expressed TLR4. As PSGL-1 serves also as a ligand
for P-selectin36, the other selectin expressed on inflamed
endothelium, we also tested P-selectin–PSGL-1 interactions37 as
trigger for Mrp8/14 release. However, we found no significant
release of Mrp8/14 via P-selectin, which led us to concentrate on
the E-selectin-dependent release of Mrp8/14. Previous intravital
microscopy studies demonstrated that E-selectin and CXCR2
cooperate in an overlapping manner to induce firm leukocyte
adhesion in TNF-a-stimulated postcapillary venules of the mouse
cremaster muscle33. Using the same mouse model, our
experiments showed that blockade of Gai-coupled signalling
through pretreatment of mice with pertussis-toxin only led to a
significant drop in leukocyte adhesion, if mice were
concomitantly pretreated with TLR4-blocking monoclonal
antibody 1A6 or Paquinimod. Additive blockade of E-selectin
did not further reduce leukocyte adhesion, underlining our
hypothesis that Mrp8/14–TLR4 engagement functions in the
same pathway as E-selectin–PSGL1.
Of note, as MRP8/14 is only found in myeloid cells (mostly in
neutrophils but also in monocytes), but not in other leukocyte
subsets such as B or T lymphocytes, the described E-selectin-
triggered and Mrp8/14-dependent mechanism of b2 integrin
activation is restricted to the myeloid lineage and might be
regarded as a specific activation signal for myeloid cell
recruitment. Although mostly neutrophils contributed to the
release of Mrp8/14 in our acute in vivo models, we found residual
Mrp8/14 serum level in mice, where PMN were depleted. This
could point to an additional release of Mrp8/14 by circulating
monocytes, which have been reported to secrete Mrp8/14 under
inflammatory conditions16. Furthermore, it was shown previously
that Paquinimod inhibits monocyte recruitment to sides of sterile
inflammation 20 h after immunization38.
Besides identifying an additional extracellular activation loop
necessary for b2 integrin activation during engagement of
myeloid cells with the inflamed endothelial lining, another














Figure 7 | Overview on MRP8/14 and its role in leukocyte recruitment in vivo. E-selectin-mediated rolling of leukocytes on inflamed endothelium
triggers E-selectin–PSGL-1-dependent release of MRP8/14. Extracellular MRP8/14 in turn binds to TLR4 and through this rapid autocrine extracellular
activation loop Rap1-GTP and b2 integrin intermediate and high-affinity activation is induced, which leads to slow rolling and firm leukocyte adhesion
on the inflamed endothelium.
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TLR4- signalling as a rapid inducer of b2 integrin activation. This
has not been described in vivo before and expands the function of
TLR4 from its role as potent stimulator of nuclear factor-kB to an
additional component of a rapid b2 integrin activation pathway
triggered through E-selectin-dependent rolling. Signalling via
TLR4 is complex, as many different ligands exist, which are able
to cause different cellular responses due to the recruitment/
activation of different adaptor/signalling molecules downstream
of TLR4. In the case of Mrp8/14, ligation of TLR4 by Mrp8/14
induces wide-ranging effects on neutrophils. This includes
cytokine and chemokine production, generation of reactive
oxygen species1 and, as shown here, rapid b2 integrin
activation. However, how MRP8/14-stimulated TLR4 signalling
pathways induce b2 integrin activation is currently not entirely
understood. We identified the involvement of MyD88 and Rap1-
GTP downstream of TLR4 stimulation. Interestingly, when we
analysed the rolling behaviour of Tlr4 / leukocytes, rolling
velocities in flow chambers coated with rmE-selectin and
rmICAM-1 were equal to those found in C57BL/6 WT mice.
Similarly, Andonegui and colleagues reported that leukocyte
rolling velocities in TNF-a-treated cremaster muscle venules were
similar between WT and Tlr4 / mice37. However, the same
study also reported that in contrast to WT mice, in which local
LPS treatment led to a significant drop in leukocyte rolling
velocities, leukocyte rolling velocities in Tlr4 / mice did not
significantly change over baseline following local stimulation with
LPS37. This implies that TLR4 is involved in regulating leukocyte
rolling velocities. However, the involvement of TLR4 does not
seem to be constitutive, but rather ligation/stimulation
dependent. This could be an explanation for the masking of the
leukocyte rolling velocity response in Tlr4 / mice. Future
studies will be necessary to further clarify this issue and work out
the precise signalling pathway of TLR4-dependent b2 integrin
activation in neutrophils and monocytes.
MRP8/14 can also bind to other receptors such as the
RAGE39,40 and Paquinimod can also affect the binding of
MRP14 to RAGE26. Therefore, we also tested a potential
involvement of neutrophil-expressed RAGE on Mrp8/14
effector functions. Interestingly, our own Mrp8/14 release
studies showed that stimulated Mrp8/14 release led only to an
increase in neutrophil surface binding of Mrp8/14 in the presence
of TLR4. These results indirectly speak against a role of
neutrophil-expressed RAGE as relevant Mrp8/14 ligand in
terms of b2 integrin activation. Furthermore, we found that
blockade of Mrp8/14 binding to TLR4 with Paquinimod
increased Rage / neutrophil rolling velocity to the same
extent as seen in C57BL/6 WT mice suggesting no role of
neutrophil-expressed RAGE in regulating Mrp8/14-dependent
slow leukocyte rolling.
TLR4 and other MRP8/14-binding molecules are also
expressed on inflamed endothelial cells and it was shown that
MRP8/14 induces a thrombogenic, inflammatory response in
HMEC cells in vitro5. The transcription of proinflammatory
chemokines like IL8 and proinflammatory molecules like ICAM-
1 was increased upon MRP8/14 treatment of HMEC cells. We
show reduced adhesion of leukocytes on inflamed endothelium in
C57BL/6 WT mice pretreated with a combination of Paquinimod
and PTx or a combination of anti-TLR4 antibody 1A6 and PTx.
Although our in vitro assays indicate that MRP8/14 exerts its
proinflammatory function via binding to TLR4 on neutrophils,
MRP8/14 binding to the inflamed endothelium may also
contribute to leukocyte recruitment during inflammation in vivo.
In summary, our results revise and expand our view on the
molecular mechanisms governing leukocyte recruitment during
inflammation by introducing a novel MRP8/14-dependent
extracellular activation loop as a modulator of the recruitment
process in vivo (Fig. 7) via bridging the rolling and adhesion
processes in an autocrine manner. MRP8/14 released from
neutrophils by E-selectin–PSGL1 interactions binds to TLR4,
which in turn stimulates a rapid signal transduction cascade
leading—via MyD88 and Rap1-GTP—to b2 integrin activation, a
necessary step for the induction of slow leukocyte rolling and firm
arrest on inflamed endothelium.
Methods
Animals. Cd44 / mice were provided by Rodger P. McEver (Cardiovacular
Biology Research Program, Oklahoma, OK, USA)41. Selpl / and Glg1 / mice
were provided by Dietmar Vestweber (Max Planck Institute for Biochemistry,
Mu¨nster, Germany)24,36. Tlr4 / mice were obtained from Admar Verschoor
(University of Munich, Germany)42. Rage / mice were provided by Angelika
Bierhaus (University of Heidelberg, Germany, deceased) and Peter Nawroth
(University of Heidelberg, Germany)43. All mice strains had been backcrossed into
C57BL/6 WT background. Glg1 / mice are embryonically lethal. Therefore, fetal
liver cell chimeras (named Glg1 / mice) were generated as described44 using
Glg1-deficient fetal liver cells adoptively transferred into lethally irradiated C57Bl/6
WT mice. C57BL/6 WT mice were obtained from the Janvier Labs (Saint
Berthevin, France). All mice were maintained at the Walter Brendel Center for
Experimental Medicine, Ludwig Maximilians Universita¨t, Munich, Germany.
Eight- to twenty-week-old male mice were used for all experiments. Animal
experiments were approved by the government Oberbayern, Germany, AZ 55.2-1-
54-2531-134/08, -175/09, -90/09 and -76/12.
Mrp8/14 release assay. For the in vitro release assay, we coated glass dishes
overnight with rmE-selectin (CD62E Fc chimera, R&D Systems, 10 mgml 1),
rmP-selectin (CD62P Fc chimera, R&D 10 mgml 1), FcR (Miltenyi Biotec GmbH,
10 mgml 1) or PBS at 4 C. Bone marrow-derived neutrophils were isolated from
C57BL/6 WT, Selpl / , Cd44 / and Glg1 / mice using EasySep mouse
neutrophil enrichment kit (STEMCELL TECHNOLOGIES) according to the
manufacturer’s protocol. Purity of isolated cells was over 90%. Glass dishes were
transferred into a 24-well plate, blocked with 5% Casein (Sigma-Aldrich) for 2 h
and washed with PBS. 5 105 neutrophils were reconstituted in HBSS buffer
(HBSS containing 1mM CaCl2 und 1mM MgCl2, 10mM HEPES, 0.25% BSA,
0.1%Glucose, pH7.4) and incubated under shaking conditions on the pre-coated
wells at 37 C for 10 or 30min. Soluble PMA (Sigma-Aldrich, 1 mM) was used as
positive control. Rat anti-mouse E-selectin antibody 9A9 (kind gift from Dr Barry
Wolitzky, MitoKor, 10 mgml 1) was used to block E-selectin-induced Mrp8/14
release. Supernatants were collected and analysed by ELISA to determine the
concentrations of Mrp8/14 as described earlier23.
For the in vivo release assay, we injected rmTNF-a (R&D Systems, 500 ng per
mouse) into the scrotum of C57BL/6 WT mice, as described earlier34. Blocking
experiments were performed by i.v. injection of rat anti-mouse antibody 9A9
(30 mg per mouse) 15min before rmTNF-a application. Neutrophil depletion was
induced via i.v. injection of 30 mg rat anti-mouse Ly6G antibody (BioLegend, 1A8)
22 h before rmTNF-a application. 100 ml of mouse blood was collected via
retroorbital bleeding before application of anti-mouse E-Selectin antibody or/and
rmTNF-a and 2 h after rmTNF-a application. Serum was separated using
Microtainer SST Tubes columns (REF 365951, Becton & Dickinson BD) according
to the manufacturer’s protocol and ELISA was used to determine the concentration
of Mrp8/14 as described earlier23.
Autocrine MRP8/14 binding to neutrophils. Bone marrow cells were isolated
from C57BL/6 WT mice. 1 106 cells were stimulated for 5min at 37 C with PBS/
0.1% BSA or soluble rmE-Selectin (CD62E Fc chimera, R&D Systems,1 mgml 1).
Rat IgG2b isotype control (eBioscience, 10 mgml 1) or rat anti-mouse TLR4
antibody (1A6, NovImmune SA, 10 mgml 1) were co-incubated with tubes
containing soluble rmE-selectin. Cells were fixed using BD FACS Lysing solution
(BD) and washed with PBS/5% BSA. Thereafter, cells were stained with polyclonal
rabbit anti-mouse Mrp14 antibody (1.5 mgml 1, Johannes Roth, University of
Mu¨nster). Donkey anti-rabbit Alexa Flour 488 (Molecular Probes/Invitrogen,
2.5 mgml 1) was used as secondary antibody. Rat anti-mouse Ly6G pacific blue
(1A8, BioLegend, 1 mgml 1) was used to define neutrophils. Amount of receptor-
bound Mrp14 on Ly6Gþ /Mrp14þ cells was determined using a Beckman Coulter
Gallios flow cytometer.
b2 Integrin activation assay. Human neutrophils were isolated from healthy
volunteer blood donors using Polymorphoprep (AXI-SHIELD PoC AS). Enriched
neutrophils (5 105 sample 1) were preincubated with Paquinimod (Active
Biotech AB, 10mgml 1), PBS/10% DMSO (carrier substance), rat anti-human
polyclonal TLR4 (PAb-hTLR4, Invivogen, 1 mgml 1) or normal rat IgG Isotype
(EMFRET Analytics & Co., 1 mgml 1) for 3min at 37 C, respectively. hMRP8/14
was obtained from Johannes Roth, University of Mu¨nster. The complex was
prepared essentially free of endotoxin contamination from human neutrophils as
previously described45. hMRP8/14 (5 mgml 1), LPS (Sigma-Aldrich, 1 mgml 1),
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PMA (Sigma-Aldrich, 1 mM) or PBS/0.1% BSA were added to vials containing
mouse anti-human b2 integrin activation antibody KIM127 (Invivo, 10 mgml 1)
or mAB 24 (Hycult Biotech, 10 mgml 1) or IgG1 Isotype control antibody
(BioLegend, 10mgml 1) and warmed up to 37 C for 5min. Preincubated
neutrophils and pre-warmed substance/antibody mix were pooled. Cells were
stimulated for another 5min at 37 C in a total volume of 40ml. Reaction was
stopped by adding 900 ml ice-cold BD FACS Lysing solution (BD) and tubes were
immediately transferred on ice. After 10min fixation time, cells were washed and
stained with goat anti-mouse PE antibody (BD Biosciences Pharmingen,
2.5 mgml 1). To define human neutrophils, cells were finally stained with mouse
anti-human CD15-FITC (VIMC6, Miltenyi Biotec GmbH, 1:100) and mouse anti-
human CD66abce-APC (TET2, Miltenyi Biotec GmbH, 1:100). Activation status of
b2 integrins was determined using a Beckman Coulter Gallios flow cytometer. In a
second set of experiments, total Mac-1 and total LFA-1 protein amount was
investigated. For this approach, mouse anti-human CD11b (ICRF44, BioLegend,
5 mgml 1) or mouse anti-human CD11a (HI111, BD Biosciences Pharmingen,
5 mgml 1) was used.
Rap1 activation assay. Human neutrophils were isolated from healthy volunteer
blood donors using a double gradient with Histopaque-1119 and 1077 (Sigma-
Aldrich). To assess active Rap1 in human neutrophils, a pull-down assay was
performed with Rap1 Activation Kit (Milipore) according to the manufacturer’s
instructions. Briefly, 4 106 human neutrophils were incubated or not with
E-selectin (1 mgml 1) or hMRP8/14 (5mgml 1) at 37 C for 5min in complete
RPMI medium. For inhibitor experiments, cells were pretreated with Paquinimod
(10 mgml 1) or rat anti-human TLR4 antibody (1mgml 1) for 2min before
adding E-selectin or hMRP8/14. Ral GDS-RBD agarose (Milipore, 25 ml) was added
to each cell extract and incubated for 50min at 4 C. Precipitates were then washed,
re-suspended in 30ml of  2 sample buffer, boiled for 10min at 95 C and sepa-
rated by 12% SDS–PAGE. Rabbit Rap1 antibody (Milipore, 1 mgml 1) was used to
detect active Rap1 (Rap1-GTP). Whole-cell lysates (10 ml) from each cell extract
before adding agarose were used to assess total levels of Rap1. The band intensity
was quantified by using the Image J software (NIH)46. Blood drawing for isolation
of human neutrophils from healthy human volunteers was performed with
informed consent and approved by the local ethics committee at the University of
Dresden, Germany.
In vitro and ex vivo flow chamber. To investigate rolling velocities, we used a
previously described flow chamber system29. Glass capillaries (Rect. Boro
Capillaries 0,04 0,40mm ID, VitroCom) were coated overnight with rmE-selectin
(CD62E Fc chimera, R&D Systems, 20 mgml 1) or a combination of rmE-Selectin
and rmICAM-1 (ICAM-1 Fc chimera, R&D Systems, 15 mgml 1) and blocked
with 5% casein (Sigma-Aldrich) for 2 h. Whole blood was collected from C57BL/6
WT, Rage / or Tlr4 / mice via the carotid artery and heparinized. Depending
on the desired condition, Paquinimod (Active Biotech AB, 10 mgml 1), rat IgG2b
(BD Biosciences Pharmingen, 10 mgml 1), rat anti-mouse TLR4 antibody 1A6
(1A6, NovImmune SA, 10 mgml 1) or Lovastatin (Calbiochem, Merck KGaA,
100mM) was added to the blood sample, respectively. Samples were preincubated
for 3min at 35 C and perfused through the microflow chambers using a high
precision perfusion pump at a shear stress level of 2.7 dyn cm 2. For ex vivo flow
chamber assays, C57BL6/WT mice were pretreated by i.p. application of either
control peptide (BIOMOL, 1mg kg 1) or MyD88 inhibitor IMG2005 (BIOMOL,
1mg kg 1) for 24 h. Carotid artery catheter was placed and mouse blood directly
perfused through the microflow chamber at a shear stress level of 3–4 dyn cm 2.
One representative field was recorded for 5min using an Olympus BX51WI
microscope with a CCD camera (model CF8/1, Kappa) and a water immersion
objective (x40/0.8 NA, Olympus). Rolling velocity of the cells was determined using
Fiji software46.
TNF-a-induced inflammation model of mouse cremaster muscle. The TNF-a-
induced inflammation model of the mouse cremaster muscle was performed as
described previously in C57BL/6 WT mice34. Briefly, C57BL/6 WT mice were
pretreated i.p. with a combination of Paquinimod (Active Biotech AB,
10mg kg 1)þ PTx (Sigma-Aldrich, 4 mg per mouse) or rat anti-mouse TLR4
antibody (1A6, NovImmune SA, 100 mg per mouse)þ PTx (Sigma-Aldrich, 4 mg
per mouse). PBS/10%DMSO (carrier substance)þ PTx and rat IgG2b (eBioscience,
100mg per mouse)þPTx were used as controls, respectively. In a second set of
experiments, rat anti-mouse anti-E-selectin antibody 9A9 (100 mg per mouse) was
applied concomitantly. Depending on the desired condition and for the
investigation of in vivo rolling velocities, Paquinimod, PBS/10% DMSO, 1A6 and
rat IgG2b isotype control were applied without PTx. 500 ng of rmTNF-a (R&D
Systems, 500 ng mouse 1) was applied to the mouse scrotum 1 h later. After 2 h of
rmTNF-a application, cremaster muscle was dissected. Mean rolling velocities and
number of adherent cells per mm were determined using intravital microscopy
(Olympus BX51WI microscope, water immersion objective x20, 0.95 numerical
aperture, Olympus). All scenes were recorded using a CCD camera (model CF8/1,
Kappa) and virtual dub software for later off-line analysis. During the entire
observation, the cremaster muscle was superfused with thermo-controlled (35 C)
bicarbonate-buffered saline. Postcapillary venules under observation ranged from
20 to 40 mm in diameter. Microvascular parameters (venular diameter, venular
vessel segment length) were determined using Fiji software46.
Statistical analyses. All data were analysed and plotted using Graph Pad Prism
6.05 Software (GraphPad Software Inc.). For pairwise comparison of experimental
groups, a paired t-test was performed. Depending on the condition, we used one-
way analysis of variance with either Dunnett’s post-hoc test (comparison of
experimental groups against control) or Tukey’s post-hoc test (comparison of all
experimental groups against each other) or a two-way analysis of variance with
Tukey’s post-hoc test (comparison of paired experimental groups against each
other) for multiple comparison. P-valueso0.05 were considered statistically
significant.
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